Intravenous infusion of NAD+ versus nicotinamide riboside: retrospective tolerability pilot
IV NAD+ produced more infusion symptoms and substantially longer infusion times; exploratory metabolic changes were variable.
What this study tells us
Researchers looked back at outcomes without randomly assigning treatment. This can reveal real-world patterns, but it is weaker for proving that the treatment itself caused the result.
Commercial-clinic clients receiving IV NAD+ or IV nicotinamide riboside
n=Not stated here
IV NAD+ produced more infusion symptoms and substantially longer infusion times; exploratory metabolic changes were variable.
Retrospective, small, commercial setting, non-randomized; not an efficacy trial for anti-ageing, energy or cognition.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
IV NAD+ produced more infusion symptoms and substantially longer infusion times; exploratory metabolic changes were variable.